Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 57Myeloid 37Sarcoma 20Lymphoid 19Gastrointestinal 17CNS 10Genitourinary 7Gynecologic 5Thoracic 4Breast 4Dermatologic 3Head & Neck 2Tumor-Agnostic 1Endocrine 1

Conditions

Melanoma 3

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Imatinib Mesylate × Dermatologic × Clear all
NCT00667953 2023-03-30

Study of Temzolomide and Gleevec in Advanced Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1/2 Terminated
32 enrolled 8 charts
Dermatologic

Melanoma

NCT00074308 2018-06-20

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 10 charts
Dermatologic

Melanoma

NCT00470470 2014-12-23

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡